FDA 483 - PharmaLegacy Research LLC - July 08, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Samm Solutions, Inc (dba) BTS Research, a GLP Facility/CRO in San Diego, CA, revealed significant deficiencies in the conduct and documentation of nonclinical laboratory studies. The firm failed to adhere to study protocols, maintain adequate standard operating procedures, and ensure proper oversight by study directors and the quality assurance unit. These systemic issues compromised data integrity, led to inaccurate final reports, and resulted in disorganized archiving practices.
ID · 9fec7ac8-3afc-4f5a-a0d3-7911b8625966